EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FLT3L neutralization reduces dendritic cell numbers, T Cell activation, and salivary gland lymphocyte infiltration in the NOD.H2h4 Sjögren’s mouse model

Agata Bartczak, Dorothy Sims, Kamelia Zerrouki, Brian Naiman iD, Ariful Qadri, Anna M Hansen, Annie Lau-Kilby iD

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkaf220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Agata Bartczak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research and Medical Affairs, Amgen Inc, Thousand Oaks, CA, United States. Hauptthemen laut MEDLINE: Dendritic Cells, Sjogren's Syndrome, Salivary Glands, Lymphocyte Activation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon Therapeutics, Horizon Therapeutics PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Feline McDonough sarcoma-like tyrosine kinase 3 (FLT3)/FLT3 ligand (FLT3L) pathway is associated with pathogenesis of several autoimmune diseases, including Sjögren’s. Inflammatory signals increase FLT3L levels; FLT3L signaling promotes further inflammation through the differentiation, function, and survival of immune cells, including dendritic cells (DCs), monocytes, and B cells. Patients with Sjögren’s have elevated FLT3L levels, increased infiltration of DCs, macrophages, and B cells into salivary glands and tertiary lymphoid structures (TLS). We hypothesized that therapeutically neutralizing FLT3L may reduce inflammatory manifestations in the NOD.H2h4 spontaneous Sjögren’s mouse model. Female mice aged 15 to 17 wk, an age at which features of Sjögren’s have developed, were administered an anti-mouse FLT3L monoclonal antibody or isotype control for 8 wk. Compared with control, anti-FLT3L antibody treatment significantly reduced free serum FLT3L, splenic DC numbers, T cell activation, and salivary gland TLS (P < 0.05 for all). Neutralizing FLT3L may effectively treat Sjögren’s and other FLT3L-associated autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsSjogren's SyndromeSalivary GlandsLymphocyte ActivationMembrane ProteinsT-LymphocytesAntibodies, NeutralizingAnimalsMiceFemaleDisease Models, AnimalMice, Inbred NODHumansAntibodies, Monoclonal

Stichwörter der Autor:innen

FLT3 ligandSjögren’sT cellsautoimmunitydendritic cells

Substanzen

flt3 ligand proteinMembrane ProteinsAntibodies, NeutralizingAntibodies, Monoclonal

Autor:innen und Institutionen

  • Research and Medical Affairs, Amgen Inc, Thousand Oaks, CA, United States.
  • Research, AstraZeneca, Gaithersburg, MD, United States.

ORCID-Profile: Brian Naiman, Annie Lau-Kilby

Förderung

  • Horizon Therapeutics
  • Horizon Therapeutics PLC

Zitieren

APA

Bartczak, A., Sims, D., Zerrouki, K., Naiman, B., Qadri, A., Hansen, A. M., & Lau-Kilby, A. (2025). FLT3L neutralization reduces dendritic cell numbers, T Cell activation, and salivary gland lymphocyte infiltration in the NOD.H2h4 Sjögren’s mouse model. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf220

Vancouver

Bartczak A, Sims D, Zerrouki K, Naiman B, Qadri A, Hansen AM, et al. FLT3L neutralization reduces dendritic cell numbers, T Cell activation, and salivary gland lymphocyte infiltration in the NOD.H2h4 Sjögren’s mouse model. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf220

BibTeX
@article{Bartczak2025,
  author = {Bartczak, Agata and Sims, Dorothy and Zerrouki, Kamelia and Naiman, Brian and Qadri, Ariful and Hansen, Anna M and Lau-Kilby, Annie},
  title = {FLT3L neutralization reduces dendritic cell numbers, T Cell activation, and salivary gland lymphocyte infiltration in the NOD.H2h4 Sjögren’s mouse model},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkaf220}
}
Kostenlos starten →